Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report and Forecast 2024-2032

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Size

The global adeno-associated virus vector-based gene therapy market is expected to grow at a CAGR of 32.93% during the forecast period of 2024-2032, driven by focus on technological advancements in healthcare across the globe.

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Outlook

• The demand for Adeno-associated virus vector-based gene therapy is on the rise, intended to combat the rare diseases and cancer conditions.

• One of the major market trends includes rising mergers between key companies to provide optimized solutions for patients.

• The North America region is likely to experience notable growth in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Overview

Adeno-associated virus (AAV) vector-based gene therapy is an approach in the field of medical genetics, principally known for its safety profile and efficacy in delivering genetic material into host cells. AAV vectors are derived from a small, naturally occurring virus that is not known to cause disease in humans, which makes them an attractive tool for gene therapy.

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Growth Drivers

Increasing Collaborations and Partnerships to Affect the Market Landscape Significantly

In June 2023, Albumedix entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´s proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing. This collaboration aims to leverage Albumedix’s expertise in recombinant human albumin to improve the production processes for these vectors. The collaboration will include activities at both the CGT Catapult facility in Braintree and Albumedix's R&D center, focusing on process optimization, characterization, and formulation development of advanced therapies.

Surge in Development of New Products to Meet Rising Adeno-Associated Virus Vector-Based Gene Therapy Market Demand

In August 2023, Quest Diagnostics was granted breakthrough device designation from the United States Food and Drug Administration (FDA) for its AAVrh74 ELISA assay (CDx). The AAVrh74 ELISA assay is an enzyme-linked immunosorbent in vitro diagnostic assay used for the semi-quantitative detection of antibodies to AAVrh74 capsid in human serum. The designation is a process by the FDA aimed fast-tracking the development and review of medical devices and combination products that promise more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Segmentation

Market Breakup by Therapeutic Application

• Neurological Disorders

• Ophthalmic Disorders

• Muscular Disorders

• Hematological Disorders

• Metabolic Disorders

Market Breakup by Target Disease

• Rare Diseases

• Cancer

• Inherited Genetic Disorders

Market Breakup by End User

• Hospitals and Clinics

• Research Institutes and Universities

• Biotechnology and Pharmaceutical Companies

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Share

Market Segmentation Based on Application Areas is Anticipated to Witness Substantial Growth

Based on therapeutic application, the market segmentation includes neurological disorders, ophthalmic disorders, muscular disorders, hematological disorders, and metabolic disorders. The neurological disorders have seen significant growth which can be attributed to an increasing prevalence of neurological diseases like Alzheimer’s and Parkinson’s, where AAV vector show promise in transporting genetic material directly to the brain. With the progress in research and clinical trials, the potential for treating complex diseases is expanding, thereby providing the market with significant growth.

For targeting retinal cells, AAV vectors are suitable and makes then ideal in treating inherited retinal diseases. Innovations in vector engineering and delivery techniques are considered to improve safety and efficacy of treatment, propelling significant market growth in the ophthalmic sector.

Rare Disease Target is Expected to Lead the Market Share

Based on target disease, the market constitutes rare diseases, cancer, and inherited genetic disorders. Rare disease segment benefits from regulatory support as orphan drug designations that provide benefit like market exclusivity and tax incentives. The emphasis on rare diseases, which often have limited effective treatment options fuels a significant part of research and development in AAV vector gene therapy. With advancements in target and vector optimization the potential to develop curative therapies is high.

The use of AAV vector in oncology to transport the tumor suppressor genes or suicide genes into cancer cells is growing. With the rising incidence of cancer worldwide along with limitations of current therapies in terms of side effects and specificity, there is strong investment and research in this domain. As AAV-based therapies for cancer advance through clinical trials and receive approvals, this segment is poised for rapid growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Adeno-Associated Virus Vector-Based Gene Therapy Market Analysis by Region

Regionally, the market report offers an insight into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is dominating the regional landscape, owing to the advantage of having advanced biotechnological technologies, substantial healthcare expenditure and supportive regulatory policies. The presence of major pharmaceutical companies and several ongoing clinical trials are anticipated to drive the market’s growth.

Europe is expected to witness significant growth. It is fueled by strong government collaboration and funding between private and public sectors in research. Strong regulatory framework and high standards for patient care enables rapid adoption of advanced therapies such as gene therapies.

Leading Players in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Arya Sciences Acquisition Corp.

• Pfizer Inc.

• BioMarin Pharmaceutical Inc.

• Bayer AG

• Coave Therapeutics

• MeiraGTx Limited

• Neurocrine Biosciences, Inc.

• Biogen, Inc.

• Sangamo Therapeutics

• Sarepta Therapeutics, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Questions Answered in the Global Adeno-Associated Virus Vector-Based Gene Therapy Market Report

• What is the global adeno-associated virus vector-based gene therapy market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on therapeutic application?
• What is the market breakup based on target disease?
• Who are the major end users in the market?
• Where does adeno-associated virus vector-based gene therapy find its application?
• What are the major factors aiding the global adeno-associated virus vector-based gene therapy market demand? 
• How has the adeno-associated virus vector-based gene therapy market performed so far and how is it anticipated to perform in the coming years?
• What are the major market trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the prevalence and incidence of neurological diseases affect the market landscape?
• How does the rise in the neurological conditions impact the market size?
• What therapeutic application will dominate the market share? 
• Which target disease is expected to have a high market value in the coming years?
• Who are the key players involved in the adeno-associated virus vector-based gene therapy market?
• What is patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

Adeno-Associated Virus Vector-Based Gene Therapy Market Report Snapshots

Adeno-Associated Virus Vector-Based Gene Therapy Market Size

Adeno-Associated Virus Vector-Based Gene Therapy Market Growth

Adeno-Associated Virus Vector-Based Gene Therapy Market Trends

Adeno-Associated Virus Vector-Based Gene Therapy Market Share

Adeno-Associated Virus Vector-Based Gene Therapy Market Regional Analysis

Adeno-Associated Virus Vector-Based Gene Therapy Companies